1874 related articles for article (PubMed ID: 19228602)
21. [Optimal duration of anticoagulation of venous thromboembolism].
Savina EN; Couturaud F
J Mal Vasc; 2011 Dec; 36 Suppl 1():S28-32. PubMed ID: 22177766
[TBL] [Abstract][Full Text] [Related]
22. Long-term management of patients after venous thromboembolism.
Kearon C
Circulation; 2004 Aug; 110(9 Suppl 1):I10-8. PubMed ID: 15339876
[TBL] [Abstract][Full Text] [Related]
23. Elevated white blood cell count and outcome in cancer patients with venous thromboembolism. Findings from the RIETE Registry.
Trujillo-Santos J; Di Micco P; Iannuzzo M; Lecumberri R; Guijarro R; Madridano O; Monreal M;
Thromb Haemost; 2008 Nov; 100(5):905-11. PubMed ID: 18989537
[TBL] [Abstract][Full Text] [Related]
24. The negative predictive value of D-dimer on the risk of recurrent venous thromboembolism in patients with multiple previous events: a prospective cohort study (the PROLONG PLUS study).
Ageno W; Cosmi B; Ghirarduzzi A; Santoro R; Bucherini E; Poli D; Prisco D; Alatri A; Pengo V; Galli L; Dentali F; Palareti G
Am J Hematol; 2012 Jul; 87(7):713-5. PubMed ID: 22488507
[TBL] [Abstract][Full Text] [Related]
25. Anticoagulation strategies for venous thromboembolism: moving towards a personalised approach.
Black SA; Cohen AT
Thromb Haemost; 2015 Oct; 114(4):660-9. PubMed ID: 26084864
[TBL] [Abstract][Full Text] [Related]
26. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.
Ay C; Vormittag R; Dunkler D; Simanek R; Chiriac AL; Drach J; Quehenberger P; Wagner O; Zielinski C; Pabinger I
J Clin Oncol; 2009 Sep; 27(25):4124-9. PubMed ID: 19636003
[TBL] [Abstract][Full Text] [Related]
27. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study.
Kearon C; Spencer FA; O'Keeffe D; Parpia S; Schulman S; Baglin T; Stevens SM; Kaatz S; Bauer KA; Douketis JD; Lentz SR; Kessler CM; Moll S; Connors JM; Ginsberg JS; Spadafora L; Julian JA;
Ann Intern Med; 2015 Jan; 162(1):27-34. PubMed ID: 25560712
[TBL] [Abstract][Full Text] [Related]
28. Value of D-dimer testing for the exclusion of pulmonary embolism in patients with previous venous thromboembolism.
Le Gal G; Righini M; Roy PM; Sanchez O; Aujesky D; Perrier A; Bounameaux H
Arch Intern Med; 2006 Jan; 166(2):176-80. PubMed ID: 16432085
[TBL] [Abstract][Full Text] [Related]
29. Deep-vein thrombosis in malignancy: how long should patients be treated, and with what?
Merli GJ
Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S27-34. PubMed ID: 19530157
[TBL] [Abstract][Full Text] [Related]
30. Preventing recurrent venous thromboembolism.
Drug Ther Bull; 2009 Apr; 47(4):38-40. PubMed ID: 19357297
[TBL] [Abstract][Full Text] [Related]
31. Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment.
Santamaria MG; Agnelli G; Taliani MR; Prandoni P; Moia M; Bazzan M; Guazzaloca G; Ageno W; Bertoldi A; Silingardi M; Tomasi C; Ambrosio GB;
Thromb Res; 2005; 116(4):301-6. PubMed ID: 16038714
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.
Eriksson H; Lundström T; Wåhlander K; Clason SB; Schulman S;
Thromb Haemost; 2005 Sep; 94(3):522-7. PubMed ID: 16268466
[TBL] [Abstract][Full Text] [Related]
33. D-dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis.
Cosmi B; Legnani C; Cini M; Favaretto E; Palareti G
Thromb Res; 2008; 122(5):610-7. PubMed ID: 18304616
[TBL] [Abstract][Full Text] [Related]
34. Duration of anticoagulant therapy for patients with venous thromboembolism.
Garcia D
Thromb Res; 2008; 123 Suppl 1():S62-4. PubMed ID: 18823648
[TBL] [Abstract][Full Text] [Related]
35. Venous thromboembolism and cancer: risks and outcomes.
Lee AY; Levine MN
Circulation; 2003 Jun; 107(23 Suppl 1):I17-21. PubMed ID: 12814981
[TBL] [Abstract][Full Text] [Related]
36. Impact and clinical significance of recurrent venous thromboembolism.
Labropoulos N; Spentzouris G; Gasparis AP; Meissner M
Br J Surg; 2010 Jul; 97(7):989-99. PubMed ID: 20632262
[TBL] [Abstract][Full Text] [Related]
37. Venous thromboembolism during pregnancy or postpartum: findings from the RIETE Registry.
Blanco-Molina A; Trujillo-Santos J; Criado J; Lopez L; Lecumberri R; Gutierrez R; Monreal M;
Thromb Haemost; 2007 Feb; 97(2):186-90. PubMed ID: 17264945
[TBL] [Abstract][Full Text] [Related]
38. Impact of sex and traditional cardiovascular risk factors on the risk of recurrent venous thromboembolism: results from the German MAISTHRO Registry.
Linnemann B; Zgouras D; Schindewolf M; Schwonberg J; Jarosch-Preusche M; Lindhoff-Last E
Blood Coagul Fibrinolysis; 2008 Mar; 19(2):159-65. PubMed ID: 18277138
[TBL] [Abstract][Full Text] [Related]
39. Anticoagulation period in idiopathic venous thromboembolism. How long is enough?
Farraj RS
Saudi Med J; 2004 Jul; 25(7):848-51. PubMed ID: 15235686
[TBL] [Abstract][Full Text] [Related]
40. The optimal duration of anticoagulation in patients with venous thromboembolism: how long is long enough?
Prandoni P; Piovella C; Spiezia L; Dalla Valle F; Pesavento R
Panminerva Med; 2012 Mar; 54(1):39-44. PubMed ID: 22278115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
